Form 4: BioLife Solutions EVP Sells Shares Under 10b5-1 Trading Plan

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, sold 523 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Aby J. Mathew, the EVP & Chief Scientific Officer of BioLife Solutions, sold 523 shares of the company's common stock on November 26, 2024.
• The shares were sold at a price of $27.2 per share.
• This transaction was executed under a pre-existing Rule 10b5-1 trading plan adopted by Mr. Mathew on February 24, 2022.
• The sale was made to satisfy tax withholding obligations related to the vesting of restricted stock.
• Following the transaction, Mr. Mathew directly owns 283,919 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for executives who have pre-arranged trading plans to manage their stock holdings and tax obligations. It is not unusual for executives to sell shares to cover tax liabilities related to vesting stock options or restricted stock.

Comparison to Industry Standards

• Many executives at publicly traded companies use 10b5-1 trading plans to avoid accusations of insider trading.
• These plans are common practice and allow for scheduled sales of stock to cover tax obligations or for personal financial planning.
• The sale of 523 shares is a relatively small transaction compared to the total holdings of the executive and is not unusual.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders as it is a small sale by an executive under a pre-arranged plan.

Key Dates

Keywords

BioLife Solutions, BLFS, insider trading, stock sale, 10b5-1 plan, executive, share transaction, equity